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Mutations in VCP cause multisystem degenera-
tion impacting the nervous system, muscle, and/or
bone. Patients may present with ALS, Parkinsonism,
frontotemporal dementia, myopathy, Paget’s dis-
ease, or a combination of these. The disease
mechanism is unknown. We developed a Drosophila
model of VCP mutation-dependent degeneration.
The phenotype is reminiscent of PINK1 and parkin
mutants, including a pronounced mitochondrial
defect. Indeed, VCP interacts genetically with the
PINK1/parkin pathway in vivo. Paradoxically, VCP
complements PINK1 deficiency but not parkin
deficiency. The basis of this paradox is resolved
by mechanistic studies in vitro showing that VCP
recruitment to damaged mitochondria requires
Parkin-mediated ubiquitination of mitochondrial
targets. VCP recruitment coincides temporally with
mitochondrial fission, and VCP is required for
proteasome-dependent degradation of Mitofusins
in vitro and in vivo. Further, VCP and its adaptor
Npl4/Ufd1 are required for clearance of damaged
mitochondria via the PINK1/Parkin pathway, and
this is impaired by pathogenic mutations in VCP.
INTRODUCTION
Mutations in valosin-containing protein (VCP) cause adominantly
inherited, multisystem degenerative disease that affects muscle,
bone, and brain. This condition has been called ‘‘IBMPFD’’ to
reflect the clinical manifestations of inclusion body myopathy
(IBM), frontotemporal dementia (FTD), and Paget’s disease of
bone (PDB) in affected families (Watts et al., 2004). More
recently, the term multisystem proteinopathy (MSP) has beenadopted for this disorder to reflect the expanding phenotypic
spectrum of VCP-related diseases, which include sporadic or
familial amyotrophic lateral sclerosis (ALS) (Abramzon et al.,
2012; Johnson et al., 2010), hereditary spastic paraplegia
(de Bot et al., 2012), parkinsonism (Kimonis et al., 2008; Spina
et al., 2013), and Parkinson’s disease (Spina et al., 2013).
Thus, mutations in a single gene can manifest as any of several,
common, age-related degenerative diseases. There does not
appear to be genotype-phenotype correlation to account for
these different clinical manifestations (Ju and Weihl, 2010a;
Mehta et al., 2012). Indeed, the striking pleiotropy associated
with VCP mutations is frequently observed within single pedi-
grees where individuals share not only the same missense
mutation but also much genetic background in common.
The mechanism whereby mutations in VCP cause disease is
unknown, as is the basis for the phenotypic pleiotropy.
VCP is a type II member of theATPase associated with diverse
cellular activities (AAA+) family of proteins (Jentsch and Rumpf,
2007). VCP functions in a plethora of processes, including cell-
cycle regulation, DNA repair, organelle biogenesis, proteotoxic
stress response, endoplasmic reticulum-associated degrada-
tion, endolysosomal sorting, and autophagosome biogenesis
and maturation (Braun et al., 2002; Jentsch and Rumpf, 2007;
Ju and Weihl, 2010b; Krick et al., 2010; Rabinovich et al.,
2002; Ritz et al., 2011; Tresse et al., 2010; Ye et al., 2001).
VCP functions as a ‘‘segregase’’ that extracts ubiquitinated
proteins from multimeric complexes or structures for recycling
or degradation by the proteasome (Ye et al., 2005). The diversity
in VCP activities reflects its ability to interact with a diverse array
of adaptor proteins via the N-domain, which in turn enables VCP
to interact specifically with a broad array of substrates. The
conformation of VCP’s N-domain is regulated allosterically by
the status of nucleotide occupancy (ATP versus ADP) in the
nucleotide binding pocket (Tang et al., 2010). Thus, ATP
hydrolysis in the D1 domain permits VCP to adopt distinct
conformations and interact with distinct subsets of adaptors.
All disease-causing mutations in VCP are missense mutations
at the interface between the N-domain and the adjacent D1Neuron 78, 65–80, April 10, 2013 ª2013 Elsevier Inc. 65
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Figure 1. dVCP Mutation-Dependent Motor Neuron and Muscle Phenotypes in Drosophila
(A) Expression of exogenous wild-type dVCP in motor neurons with the driver OK371-GAL4 does not impact viability as assessed by rates of eclosion as adults.
In contrast, expression of mutant dVCP (R152H) leads to a high rate of pupal lethality. The flies that do eclose die shortly thereafter. Error bars indicate
standard error.
(B) Expression of mutant dVCP (but not wild-type) inmotor neurons results in a locomotor defect as assessed bymonitoring crawling behavior of 3rd-instar larvae.
Error bars indicate standard error.
(C) Expression of mutant dVCP (but not wild-type) in motor neurons results in abnormal NMJ morphology with reduced total bouton numbers. NMJs at muscle 4
were used for all analyses. Error bars indicate standard error.
(D) The abnormal NMJs in flies expressing mutant dVCP in motor neurons results in a frequent ‘‘ghost boutons’’ in which presynaptic structure lacks appositional
postsynaptic structure. Ghost boutons are very rarely observed in control animals or animals expressing wild-type dVCP. Error bars indicate standard error.
(legend continued on next page)
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VCP and the PINK1/Parkin PathwayATPase domain, which abuts the nucleotide binding pocket in
D1. Indeed, crystallographic analysis has confirmed that disease
mutations alter the shape of the nucleotide binding pocket, alter
nucleotide loading, and impair the normal reordering of the
N-domain structure that permits cycling between alternative
conformations (Tang et al., 2010). As a consequence, the
balance of VCP-adaptor interactions is altered, enhancing the
interaction of VCPwith some adaptors while diminishing interac-
tion with others (Ferna´ndez-Sa´iz and Buchberger, 2010).
The central question concerning the pathogenesis of
VCP-related disease is which functions of VCP are altered by
disease-causing mutations. To address this question in an
unbiased way, we generated a Drosophila model that captures
VCP mutation-dependent degeneration. Some aspects of this
Drosophila model are reminiscent of the phenotypes observed
in PTEN-induced putative kinase 1 (PINK1) and parkin mutant
flies. Indeed, we demonstrate genetic interactions that place
VCP downstream of the PINK1/Parkin pathway in vivo. Mecha-
nistic studies in vitro reveal that VCP is recruited to mitochondria
in a manner that requires Parkin-dependent ubiquitination of
mitochondrial proteins. Moreover, VCP is essential to the regu-
lated degradation of membrane proteins, including Mitofusins,
and clearance of damaged mitochondria. Most importantly,
these studies reveal that this function of VCP is impaired by path-
ogenic mutations.
RESULTS
Recapitulation of VCPMutation-Dependent Phenotypes
in Motor Neurons and Muscle in Drosophila
The species Drosophila melanogaster has a single, highly
conserved ortholog of human VCP called dVCP. We developed
a Drosophila model of VCP-related disease by introducing
disease-homologous mutations into dVCP. Expression directed
to the eye of these animals resulted in mutation-dependent eye
degeneration despite equal levels of transgene expression
(Ritson et al., 2010). Expression of wild-type dVCP in motor
neurons with the driver OK371-GAL4 did not impact fly viability,
whereas motor neuron expression of mutant dVCP resulted in
substantial pupal lethality (Figure 1A). The few adult escapers
expressing mutant dVCP in motor neurons died shortly after
eclosion. In 3rd-instar larval animals, a mutation-dependent
locomotor phenotype was evident, as documented in an assay
of larval crawling (Figure 1B). Evaluation of the neuromuscular
junction (NMJ) in these animals revealed a striking mutation-
dependent morphological phenotype that included reduced
numbers of synaptic boutons, an accumulation of ghost
boutons, and reduced density of active zones (Figures 1C–1E
and Figure S1, available online). Evaluation of NMJ morphology
in rare surviving mutant dVCP adults also revealed morpholog-
ical defects including an accumulation of synaptic footprints
consistent with denervation (Figure S2). Consistent with our
observations in motor neurons, expression of dVCP in muscle(E) Representative images of NMJs from the genotypes indicated. The arrowhea
(F) Hemithoraces stained with phalloidin from control flies (MHC-GAL4) and flies
show a mutation-dependent myopathy at 103 and a disruption of sarcomere
morphology with numerous swollen mitochondria with disrupted cristae. See alswith the driver MHC-GAL4 resulted in mutation-dependent
muscle degeneration and a dropped wing phenotype (Figure 1F
and data not shown). Many of these flies reached adulthood,
which facilitated histological analysis as well as genetic interac-
tion studies. Histological examination of thoracic flight muscle
in these flies revealed evidence of pronounced myopathy in
flies expressing mutant dVCP, including atrophy of individual
muscles and loss of normal sarcomere architecture (Figure 1F).
Ultrastructural examination of muscle tissue by transmission
electron microscopy (TEM) revealed marked morphological
abnormalities in mitochondria with extensive megaconia and
pleioconia (Figure 1F). Interestingly, prior phenotypic analysis
of flies expressing mutant VCP reported that degeneration
was accompanied by reduced cellular ATP levels (Chang
et al., 2011). The mechanism of altered ATP levels was not
explored in Chang et al. Nevertheless, the relevance of the
altered ATP levels was nicely demonstrated since artificial
manipulation of ATP levels modified the degenerative pheno-
type (Chang et al., 2011).
The myopathy and specific mitochondrial abnormalities
observed in dVCPmutant flies are reminiscent of the phenotypes
reported in flies null for PINK1 and Parkin (Greene et al., 2003;
Poole et al., 2008). Our interest in a possible connection to these
genes was heightened by the fact that a subset of patients with
VCP mutations present with parkinsonism or Parkinson’s
disease (Kimonis et al., 2008; Spina et al., 2013), a clinical pheno-
type also associated with mutations in PINK1 and Parkin. PINK1
and Parkin participate in a common pathway that regulatesmito-
chondrial dynamics and serve to maintain mitochondrial quality
control (Clark et al., 2006; Narendra et al., 2008, 2010; Park
et al., 2006). These observations led us to hypothesize that
VCP might be a component of the PINK1/Parkin pathway and
contribute to mitochondrial quality control. To test this hypoth-
esis, we performed epistasis studies between VCP, PINK1,
and Parkin. We determined that overexpression of VCP rescued
the degenerative phenotype associated with PINK1 deficiency,
as evidenced by suppression of thoracic indentations (Figures
2A and 2B) and restoration of normal locomotor function
(Figure 2C) in PINK1 null (PINK1B9). Furthermore, histological
analysis demonstrated that VCP overexpression rescued the
mitochondrial phenotype in PINK1 null flies (Figure 2D). This
rescue by VCP is similar to that observed by overexpressing
Parkin in PINK1 null flies (Clark et al., 2006; Park et al., 2006).
These results indicate that, like Parkin, VCP functions down-
stream of PINK1 in the mitochondrial quality-control pathway.
In contrast, VCP did not suppress the degenerative phenotype
associated with Parkin deficiency (Figures 2A–2C). These data
indicate that VCP functions upstream or in concert with Parkin
or, alternatively, independently of Parkin in supportingmitochon-
drial quality control by PINK1. To clarify the relationship between
Parkin and VCP and to elucidate the role of VCP in the PINK1/
Parkin pathway (especially in mammals), we conducted exten-
sive in vitro studies, as described below.ds point out ghost boutons in an animal expressing mutant dVCP.
expressing wild-type or mutant dVCP in muscle under control of MHC-GAL4
architecture at 1003. TEM revealed profound abnormalities in mitochondrial
o Figures S1 and S2 for further analysis.
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Figure 2. dVCP Overexpression Suppresses Degeneration Associated with PINK1 Deficiency but Not Parkin Deficiency
(A) Micrographs of fly thoraces of the indicated genotypes showing thoracic indentations (arrows) caused by parkin and PINK1 deficiency. dVCP overexpression
rescues this phenotype in PINK1-deficient flies, but not in parkin-deficient flies.
(B) Quantitation showing that overexpression of dVCP suppresses thoracic indentations in PINK1-deficient animals but actually enhances this phenotype in
parkin-deficient animals. Error bars indicate standard error.
(C) Quantitation showing that overexpression of dVCP suppresses the locomotor defect in PINK1-deficient animals but not in parkin-deficient animals. Error bars
indicate standard error.
(D) Micrographs of sections through fly thoraces showing that overexpression of dVCP suppresses the muscle and mitochondrial phenotypes in PINK1-deficient
animals.
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VCP and the PINK1/Parkin PathwayVCP Relocalizes to Mitochondria in Response to
Depolarization
Parkin is an E3 ubiquitin ligase that is rapidly recruited to mito-
chondria in a PINK1-dependent manner in response to loss
of mitochondrial membrane potential (Narendra et al., 2008,
2010). Parkin recruitment results in ubiquitination of mitochon-
dria, followed by mitochondrial fission, clustering, and subse-
quent clearance of damaged mitochondria (Matsuda et al.,
2010; Narendra et al., 2008; Narendra et al., 2010). To address68 Neuron 78, 65–80, April 10, 2013 ª2013 Elsevier Inc.the hypothesis that VCP participates in the PINK1/Parkin
pathway, we first assessed whether VCP is recruited to
mitochondria in response to depolarization. We used HeLa cells
stably expressing YFP-Parkin (HeLa cells don’t show detectable
endogenous Parkin expression, data not shown) and trans-
fected plasmids expressing VCP-mCherry and mito-Cerulean
(Cerulean fluorescent protein taggedwith amitochondrial target-
ing sequence). In untreated cells, Parkin and VCP were both
distributed diffusely with no colocalization with mitochondria.
Neuron
VCP and the PINK1/Parkin PathwayHowever, 3 hr after treatment with the mitochondrial uncou-
pling agent carbonyl cyanide m-chlorophenyl-hydrazone
(CCCP), virtually all of the YFP-Parkin and VCP-mCherry signal
colocalized with mito-Cerulean, illustrating recruitment to the
mitochondria (Figure 3A).
We also generated mouse embryonic fibroblasts (MEFs)
stably expressing mito-Cerulean to enable monitoring of mito-
chondria. These cells were cotransfected with plasmids ex-
pressing mCherry-Parkin and VCP-EGFP, which as expected
were distributed diffusely throughout untreated cells. Within
3 hr of treatment with CCCP, mCherry-Parkin and VCP-EGFP
signals were relocalized to mitochondria (Figure S3A). Notably,
in the absence of exogenous Parkin we observed no recruitment
of VCP to mitochondria in response to depolarization, suggest-
ing that VCP recruitment is Parkin-dependent (Figure S3B).
Entirely consistent with the results in HeLa cells and MEFs, we
observed that VCP also was recruited to depolarized mito-
chondria in neuroblastoma-derived Sy5y cells (Figure S4)
and myoblast-derived C2C12 cells (Figure S5). Thus, VCP is
corecruited to depolarized mitochondria in concert with Parkin
in a wide variety of cell types.
VCP Recruitment to Mitochondria Follows Parkin
To characterize mitochondrial recruitment of Parkin and VCP in
detail, we performed dynamic imaging in HeLa cells expressing
VCP-EGFP and mCherry-Parkin after treatment with CCCP.
We consistently observed that recruitment of mCherry-Parkin
to mitochondria preceded recruitment of VCP-EGFP (Figures
3B–3D and Movies S1 and S2). Indeed, in an analysis of 35
sequential movies of individual cells we found that Parkin relocal-
ized tomitochondria approximately 20min after CCCP treatment
and that VCP followed Parkin approximately 15min later (Figures
3C and 3D).
Parkin-Dependent Recruitment of VCP to Depolarized
Mitochondria in Primary Neurons
We sought to examine VCP recruitment to mitochondria in a cell
type that expresses endogenous Parkin. Entirely consistent with
our results in HeLa cells, MEFs, Sy5y cells, and C2C12 cells, we
determined that VCP relocalizes to mitochondria in primary
neurons in response to depolarization with CCCP (Figure 4).
Interestingly, this redistribution occurred throughout neuronal
cells, including the soma and axonal compartments (Figure 4).
Importantly, RNAi-mediated depletion of endogenous Parkin
prevented this relocalization of VCP to mitochondria, indicating
that VCP recruitment to mitochondria in primary neurons is
Parkin dependent just as it is in MEFs.
Mitochondrial Ubiquitination by Parkin Is Essential
for VCP Recruitment
VCP interacts with polyubiquitin chains directly and also indi-
rectly through a broad array of ubiquitin-binding adaptor
proteins (Dreveny et al., 2004). Given that Parkin is an E3 ubiqui-
tin ligase, we hypothesized that ubiquitination of mitochondria
by Parkin is a prerequisite for VCP recruitment. To test this
hypothesis, we selected a Parkinson’s disease-associated
Parkin mutant that is ubiquitin-ligase-defective due to a mis-
sense mutation (T240R) in the first RING domain. Whereaswild-type Parkin is recruited to mitochondria and mediates
ubiquitination in response to depolarization, Parkin-T240R is
recruited to mitochondria but fails to mediate ubiquitination
(Lee et al., 2010) (Figure 5A and Figure S6). Quantitative analysis
revealed that VCP was recruited to mitochondria in all cells
expressing wild-type Parkin, but no such VCP recruitment
occurred in cells transfected with Parkin-T240R despite the
fact that this mutant form of Parkin is itself recruited tomitochon-
dria (Figures 5B, 5C, and S6). We conclude that ubiquitination of
mitochondria protein(s) by Parkin is essential to VCP recruitment
to mitochondria.
VCP Contributes to Regulation of Mitochondrial
Dynamics
In considering what ubiquitination targets of Parkin might be
responsible for recruitment of VCP, we noted a consistent
temporal correlation between recruitment of Parkin and VCP
and a change in mitochondrial morphology. Specifically, we
observed that mitochondria that are fusiform at the time Parkin
and VCP are recruited become increasingly fragmented within
30 min of VCP recruitment (Figure S7A and Movie S3). This
observation is consistent with evidence that PINK1 and Parkin
regulate mitochondrial dynamics and interact genetically with
some other genes that regulate mitochondrial dynamics in
Drosophila (Clark et al., 2006; Deng et al., 2008; Park et al.,
2006; Poole et al., 2008). Moreover, it was recently reported
that PINK1 and Parkin cooperate to ubiquitinate Mitofusin 1
(Mfn1) in mammalian cells and dMfn in Drosophila (Gegg et al.,
2010; Poole et al., 2010; Ziviani et al., 2010). VCP is a
ubiquitin-dependent segregase that dissociates ubiquitinated
substrates from membrane complexes and makes them acces-
sible to degradation by the proteasome and dominant-negative
VCP has been shown to stabilize mitochondrial proteins
includingMfn (Braun et al., 2002; Rabinovich et al., 2002; Tanaka
et al., 2010; Ye et al., 2001). Thus, we hypothesized that VCP
works cooperatively with Parkin in response to PINK1 tomediate
ubiquitin-dependent degradation of Mfns by the proteasome.
Consistent with this hypothesis, we observed rapid destabili-
zation of Mfns 1 and 2 after CCCP treatment of HeLa cells stably
expressing YFP-Parkin (Figure 6A). This degradation occurred
prior to degradation of the mitochondria by the autophagic
machinery as shown by the levels of voltage-dependent anion
channel (VDAC) that remain stable until late in the time course
(Figure 6A). Moreover, Mfn 1 and 2 degradation is blocked by
the proteasome inhibitors MG-132 and epoximicin, but not by
the autophagy inhibitor bafilomycin, indicating that degradation
of Mfns 1 and 2 is mediated by the proteasome (Figures 6B
and 6C). To test the hypothesis that VCP mediates proteasomal
degradation of Mfns 1 and 2, we examined the consequences of
siRNA-mediated knockdown of VCP. Whereas nontargeting
siRNA has no effect on Mfn 1 and 2 degradation after CCCP
treatment, VCP-targeting siRNA blocks Mfn 1 and 2 degradation
by the proteasome (Figure 6D). Furthermore, immunoprecipita-
tion shows that VCP interacts with Mfn2 in vitro but only after
mitochondrial membrane depolarization (Figure 6E). Thus, we
conclude that VCP is essential for proteasome-dependent
degradation of Mfns after ubiquitination by the PINK1/Parkin
pathway.Neuron 78, 65–80, April 10, 2013 ª2013 Elsevier Inc. 69
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Figure 3. VCP Recruitment to Mitochondria Follows Parkin
(A) VCP-mCherry and Mito-Cerulean were expressed in YFP-Parkin stable HeLa cells, and all three proteins were visualized at 0 and 3 hr after addition of CCCP.
See also Figure S3A for MEFs, Figure S4 for Sy5y, and Figure S5 for C2C12.
(B) Time-lapse imaging of VCP-EGFP and mCherry-Parkin following CCCP treatment in HeLa cells. These still images were extracted from Movie S1. See also
Movie S2.
(C) Graphic representation of the timing of recruitment of Parkin and VCP to mitochondria in 35 consecutive movies. Each line represents one individual movie of
a distinct set of one to three cells.
(D) Graphic representation of the lag time before mitochondrial localization of Parkin and VCP after CCCP treatment. Results represent the sum from all cells
captured in 35 consecutive movies.
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Figure 4. VCP Recruitment to Mitochondria in Primary Neurons Is Parkin Dependent
Primary neurons were transfected with mito-dsRed and VCP-EGFP and treated with DMSO or CCCP for 48 hr. VCP-EGFP signal remained diffuse with some
accumulation in Golgi in neurons treated with DMSO but relocalized to mitochondria in neurons treated with CCCP. This relocalization was abolished by
knockdown of endogenous Parkin by siRNA.
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VCP and the PINK1/Parkin PathwayTo examine the role of VCP in the PINK1/Parkin pathway in vivo
we used a transgenic approach to monitor the influence of
altered VCP activity on the ubiquitination of the Drosophilamito-
fusin homolog, dMfn. Specifically, we developed a transgenic
line expressing an HA-tagged version of dMfn to permit tissue-specific expression. This approach permitted us to circumvent
the lethality associated with reduced VCP activity by selectively
knocking down VCP in a nonessential tissue that is also ex-
pressing the tagged version of dMfn. Using this HA-tagged
form of dMfn, we find that deficiency in either PINK1 or ParkinNeuron 78, 65–80, April 10, 2013 ª2013 Elsevier Inc. 71
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Figure 5. Mitochondrial Ubiquitination by Parkin Is Essential for VCP Recruitment
(A) Parkin-dependent mitochondrial ubiquitination. HeLa cells were transfected with EGFP-Parkin wt or Parkin T240R, treated with 10 mM CCCP for 10 hr, and
immunostained for cytochrome C (red, mitochondria) and ubiquitin (blue). Scale bars represent 10 mm. See also Figure S6.
(B) Micrographs of HeLa cells expressing VCP-mCherry and either EGFP-Parkin wt or Parkin T240R. The images are taken during the mitochondrial aggregation
stage after CCCP treatment (see Figure S6 for the full time course). Scale bars represent 10 mm.
(C) Quantification of VCP recruitment to mitochondria after CCCP treatment in HeLa cells expressing either Parkin wt or Parkin T240R. Error bars indicate
standard error from three replicates. Thirty cells were counted for each replicate.
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Figure 6. Mitofusin Degradation by the Proteasome Is Dependent on VCP
(A) Western blots in YFP-Parkin stable HeLa cells against MFN1 and 2, VDAC, and tubulin at different time points after CCCP treatment. Ubiquitinated forms of
MFNs 1/2 can be observed migrating more slowly.
(B) Western blots in YFP-Parkin stable HeLa cells against MFN1/2, VDAC, and tubulin. Cells were treated for 12 hr with CCCP and either proteasome inhibitors
(MG132 or epoxomicin) or the autophagy inhibitor bafilomycin. Ubiquitinated forms of MFN1/2 can be again observed migrating more slowly, particularly with
proteasome inhibition.
(C) Quantification of total MFN expression levels normalized against tubulin in YFP-Parkin stable HeLa cells treated for 12 hr with CCCP and either proteasome
inhibitors (MG132 or epoxomicin) or the autophagy inhibitor bafilomycin. Error bars indicate standard deviation from triplicates.
(D) Knockdown of VCP stabilizes MFNs 1 and 2. Western blots in YFP-Parkin stable HeLa cells against MFN1/2, VCP, and tubulin. Cells were transfected with
nontargeting or VCP-targeting siRNA and treated for 12 hr with DMSO or CCCP.
(E) FLAG IP in HeLa cells cotransfected with YFP-Parkin and VCP-FLAG and treated with CCCP for the indicated times. Immunoprecipitation samples were
immunoblotted against MFN1/2 and VCP. After mitochondrial depolarization VCP interacts with MFN2.
(F) Total dMfn-HA accumulates in PINK1B9 (lane 2) and park25 (lane 3) null mutants. Notably, ubiquitinated dMfn is decreased in PINK1B9 null mutants (lane 2) and
absent in park25 null mutants (lane 3).
(G) Overexpression of dVCP in the compound eye destabilizes dMfn-HA (lane 1), whereas knockdown of endogenous dVCP in the compound eye leads to
accumulation of ubiquitinated dMfn-HA (lane 3).
(H) Immunoprecipitation of HA-dMfn and endogenous (protein-trap) GFP-dVCP from Drosophila brain extract.
Neuron
VCP and the PINK1/Parkin Pathwayresults in accumulation of total dMfn (Figure 6F), as previously
described for endogenous dMfn (Deng et al., 2008; Ziviani
et al., 2010). Despite this accumulation, little ubiquitinated
dMfn is detected in PINK1-deficient flies and no ubiquitinated
dMfn is detected in parkin-deficient flies, consistent with the
roles of PINK1 and Parkin in mediating dMfn ubiquitination (Fig-ure 6F). Using our system, we found that dVCP levels strongly
influence dMfn stability in vivo: overexpression of dVCP
eliminates dMfn from detection (Figure 6G, lane 1), whereas
RNAi-mediated knockdown of endogenous dVCP leads to accu-
mulation of ubiquitinated dMfn (Figure 6G, lane 3). We also
confirmed that dVCP coimmunoprecipitates dMfn in vivo inNeuron 78, 65–80, April 10, 2013 ª2013 Elsevier Inc. 73
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Figure 7. VCP and Ufd1/Npl4 Are Essential for Clearance of Damaged Mitochondria
(A) Immunostaining against TOM20 (red) in MEFs transfected with YFP-Parkin (green) and nontargeting or VCP-targeting siRNA. Cells were treated with DMSO or
CCCP for 24 hr.
(B) Immunoblot of VCP and GAPDH in MEFs transfected with nontargeting or VCP-targeting siRNA.
(C) Quantification of VCP normalized against GAPDH in cells transfected with nontargeting or VCP-targeting siRNA. Error bars indicate standard deviation from
triplicates.
(D) Quantification of cells with mitochondrial clearance. Cells were treated for 24 hr with DMSO or CCCP. At least 30 cells were counted for each sample. Errors
bars indicate standard error from three independent replicates. See also Figure S5 for C2C12 cells.
(E) Quantification of cells with residual aggregates of mitochondria. Cells were treated for 24 hr with DMSO or CCCP.
(legend continued on next page)
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VCP and the PINK1/Parkin PathwayDrosophila (Figure 6H). These observations are consistent with
our hypothesis that dVCP serves to mediate degradation of
ubiquitinated dMfn by the proteasome.
VCP Knockdown Impairs Clearance of Damaged
Mitochondria
Given that VCP recruitment is dependent on mitochondrial
ubiquitination by Parkin and that abnormal mitochondria accu-
mulate in VCP mutant Drosophila, we hypothesized that VCP is
involved in the process of PINK1/Parkin-dependent clearance
of damaged mitochondria. To test this hypothesis, we examined
the impact of VCP knockdown on the efficiency of PINK1/Parkin-
dependent mitochondrial clearance. We overexpressed YFP-
Parkin in MEFs with RNAi-mediated knockdown of VCP or in
control MEFs with nontargeting siRNA, and we monitored mito-
chondrial clearance after CCCP treatment. Twenty-four hours
after CCCP treatment, approximately 70%of cells cotransfected
with YFP-Parkin and nontargeting siRNA had completely cleared
their mitochondria (Figures 7A–7D), consistent with previous
observations (Narendra et al., 2008). In contrast, cells with
YFP-Parkin and VCP-targeting siRNA failed to clear these
depolarized mitochondria (Figures 7A–7D). We determined that
VCP is also essential for Parkin-dependent clearance of depolar-
ized mitochondria in C2C12 myoblast cells (Figure S5). Notably,
we observed residual, prominent mitochondrial clusters in many
cells that failed to clear mitochondrial in response to depolariza-
tion (Figures 7A, 7E, 7F, and 7I).
To rule out the possibility that knockdown of VCP merely
delays mitochondrial clearance, we carefully monitored the
kinetics of YFP-Parkin recruitment, as well as mitochondrial
aggregation and clearance, throughout a 24 hr window. In cells
without VCP knockdown, YFP-Parkin is recruited to mitochon-
dria within 30 min, mitochondria aggregate within 3 hr, and
mitochondrial clearance occurs within 10–12 hr. We found that
VCP knockdown did not alter the kinetics of YFP-Parkin recruit-
ment or mitochondrial aggregation, but that mitochondrial
clearance never occurred (Figures S7B–S7D and data not
shown). Thus, VCP is essential for PINK1/Parkin-mediated mito-
chondrial clearance after depolarization, although mitochondrial
aggregation can occur independent of VCP.
The Ufd1/Npl4 Complex Is Recruited to Depolarized
Mitochondria in Concert with VCP and Is Required for
Clearance of Damaged Mitochondria
VCP interacts with a variety of adaptor proteins via the
N-domain, which enables VCP to serve as a ubiquitin-dependent
segregase for a broad array of substrates. In some cases these
substrates are targeted for degradation by the proteasome and
in this activity VCP often works in concert with the Ufd1/Npl4
complex. We found the Ufd1 and Npl4 are each recruited to
depolarized mitochondria in concert with Parkin and VCP(F) Immunostaining against TOM20 (red) in MEFs transfected with YFP-Parkin (gr
treated with DMSO or CCCP for 24 hr. (Cells treated with DMSO are shown in F
(G) Real-time PCR quantification of mRNA levels of Ufd1, Npl4, or p47 after trea
(H) Quantification of cells with mitochondrial clearance in the setting of Ufd1, Np
(I) Quantification of cells with residual aggregates of mitochondria. Cells were tr
sample. Errors bars indicate standard error from three independent replicates.(Figures S8A and S8B). The specificity of this adaptor recruit-
ment is confirmed by evidence that the alternative adaptor p47
is not recruited to mitochondria in response to depolarization
(Figures S8A and S8B). Further, we show that mitochondrial
clearance following depolarization is dependent not only on
Parkin and VCP but also on Ufd1 and Npl4 and is not influenced
by depletion of p47 (Figures 7F–7I and Figure S8C).
Mutant VCP Impairs Clearance of Damaged
Mitochondria
To confirm the involvement of VCP in mitochondrial clearance
and investigate the influence of a disease-associated VCP
mutation on this phenomenon, we examined the impact of over-
expressing catalytically dead (VCP-CD) or disease-associated
mutant VCP (VCP-A232E). The VCP-CD mutant was created
by introducing mutations that impair both ATPase domains
(E305Q/E578Q). VCP-CD functions as a dominant negative
when expressed exogenously and has been extensively used
to interrogate VCP functions (Dalal et al., 2004). The VCP-
A232E missense mutation causes multisystem proteinopathy,
a dominantly inherited multisystem degeneration that can pre-
sent as Parkinson’s disease, frontotemporal dementia, amyotro-
phic lateral sclerosis, inclusion body myopathy, Paget’s disease
of bone, hereditary spastic paraplegia, or a combination of these
(Guinto et al., 2007; Johnson et al., 2010; Watts et al., 2004).
To assess the impact of these mutations on mitochondrial
clearance we coexpressed mCherry-Parkin with either wild-
type (VCP-wt) or mutant VCP (VCP-CD or VCP-A232E) in mito-
Cerulean stable MEFs and quantified mitochondrial clearance
in response to depolarization with CCCP. In cells cotransfected
with VCP-wt, mitochondria were completely cleared 24 hr post-
CCCP in 70% of cells, as expected (Figures 8A and 8B). In
contrast, cells expressing VCP-CD or VCP-A232E failed to clear
mitochondria (Figures 8A and 8B). Instead, we observed mito-
chondrial aggregates with colocalized Parkin and mutant VCP
in most cells (Figures 8A and 8C). We also examined mitochon-
drial clearance in C2C12 myoblast cells and determined that
cells expressing VCP-CD or VCP-A232E failed to clear mito-
chondria (Figures S5E–S5G). Thus, VCP is essential to mito-
chondrial clearance in response to CCCP and a disease-causing
mutation in VCP impairs this process.
DISCUSSION
VCP is an essential molecular chaperone that contributes to
a broad array of cellular activities. The central question con-
cerning the pathogenesis of VCP-related disease is as follows:
which functions of VCP are impaired by disease-causing
mutations? To address these questions in an unbiased way,
we generated a Drosophila model that captures VCP mutation-
dependent degeneration. We found that these animals haveeen) and nontargeting siRNA or siRNA targeting Ufd1, Npl4, or p47. Cells were
igure S8C.)
tment with the individual siRNAs.
l4, or p47 knockdown.
eated for 24 hr with DMSO or CCCP. At least 30 cells were counted for each
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Figure 8. Overexpression of VCP-CD or A232E Inhibits Clearance of Damaged Mitochondria
(A) Imaging VCP-EGFP and mCherry-Parkin in Mito-Cerulean stable MEFs 24 hr after addition of CCCP. Cells were transfected with VCP-wt, CD, or disease
mutant A232E -EGFP. Scale bars represent 10 mm.
(B) Quantification of cells with mitochondrial clearance. Cells were prepared as described in (A). At least 30 cells were counted for each sample. Errors bars
indicate standard error from three independent replicates.
(C) Quantification of cells with residual aggregates of mitochondria. Cells were prepared as described in (A). At least 30 cells were counted for each sample. Errors
bars indicate standard error from three independent replicates. C2C12 cell data are shown in Figures S5E–S5G.
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VCP and the PINK1/Parkin Pathwaya mitochondrial phenotype resembling that observed in PINK1
and parkin mutant flies (Figure 1). Indeed, this impression was
validated by the finding that overexpression of dVCP comple-
ments PINK1 and rescues the degeneration and mitochondrial
phenotype observed in PINK1 null flies, placing VCP down-
stream of PINK1 in the mitochondrial quality control pathway
(Figure 2). This is similar to prior observations that overexpres-
sion of parkin complements PINK1 and rescues PINK1 null flies
(Clark et al., 2006; Park et al., 2006). We were intrigued, there-
fore, when overexpression of dVCP failed to complement parkin.
This paradox was resolved by studies in vitro demonstrating that
VCP recruitment to mitochondria is Parkin dependent. Specifi-
cally, we showed that VCP recruitment to mitochondria follows
Parkin temporally and depends on Parkin-mediated ubiquitina-
tion of mitochondrial substrates (Figures 3–5). VCP is re-
quired for proteasome-dependent degradation of ubiquitinated
Mitofusin-1 and Mitofusin-2 in vitro (Figure 6 and Tanaka et al.,
2010) and the Drosophila homolog dMfn in vivo (Figure 6).
Furthermore, we showed that VCP and its adaptor complex
Ufd1/Npl4 are required for clearance of damaged mitochondria
(Figure 7) and that this function is impaired by pathogenic muta-
tions in VCP (Figure 8).
Mutations in VCP cause a dominantly inherited, multisystem
degenerative disease that affects muscle, bone, and brain.
This condition has been called ‘‘IBMPFD’’ to reflect the clinical
manifestations of IBM, FTD, and PDB in affected families (Watts
et al., 2004). More recently, the term MSP has been adopted for
this disorder to reflect the expanding phenotypic spectrum of
VCP-related diseases. Pathogenic VCP mutations have been
identified in more common diseases such as sporadic and
familial forms of ALS (Johnson et al., 2010), FTD (Koppers
et al., 2012), IBM (Shi et al., 2012), and PDB (Chung et al.,
2011). Themechanismwherebymutations in VCP cause disease
is incompletely understood. The studies presented here demon-
strate not only that VCP functions within the PINK1/Parkin
pathway of mitochondrial quality control, but that disease-
causing mutations in VCP impair this pathway.
VCP is an essential gene—nullizygousmutations in VCP cause
early embryonic lethality in mice (Mu¨ller et al., 2007). Thus, the
mechanism of VCP-related disease is not likely to be caused
by a simple loss of function. Indeed, the autosomal-dominant
inheritance pattern of VCP-related disease and the ability to
recapitulate disease by overexpression of mutant forms of VCP
in a wild-type background in cells or animals (Badadani et al.,
2010; Custer et al., 2010; Ritson et al., 2010; Weihl et al., 2007)
both argue in favor of a dominant molecular mechanism, result-
ing in a toxic gain of function, a dominant-negative function, or
possibly a combination of both.
Structurally, VCP is similar to other type II AAA+ proteins such
as NSF and ClpA in that it functions as a homohexameric barrel
(White and Lauring, 2007). This homohexameric structure
suggests the possibility of a dominant-negative effect imposed
by disease mutations. Thus, comingling of wild-type and mutant
VCP proteins in the same homohexamer could lead to dominant
impairment of wild-type VCP function. However, it is clear that
loss of function alone through a dominant-negative mechanism
cannot account for the phenotype observed in Drosophila
expressing mutant VCP. If this were the case, coexpression ofexogenous wild-type dVCP would be expected to suppress
the degeneration caused by mutant dVCP, but it does not.
Indeed, coexpression of exogenous wild-type dVCP enhances
the degeneration that accompanies mutant dVCP expression
(Chang et al., 2011).
So, howdo diseasemutations impact VCP function? As stated
above, the N-domain of VCP alternates between distinct con-
formations and this is regulated by the nucleotide occupancy
in the D1 domain. These distinct conformations bind to distinct
subsets of adaptors that are responsible for different VCP func-
tions. Crystallographic studies of mutant forms of VCP suggest
that disease-causing mutations alter nucleotide occupancy in
the D1 domain, causing VCP to be locked into a fixed conforma-
tion, consequently interfering with interaction of the N-terminal
domain with a subset of adaptor proteins (Tang et al., 2010).
Thus, disease mutations are predicted to enhance interaction
with some adaptors andmitigate interaction with other adaptors,
which could amplify some VCP functions and diminish others.
Indeed, this precise observation was made when the impact of
VCP mutations on several adaptor interactions was examined
in vitro (Ferna´ndez-Sa´iz and Buchberger, 2010).
Consistent with this hypothesis regarding an imbalance in VCP
function, we and others have recently shown that disease
mutations in VCP do not impair endoplasmic reticulum-associ-
ated degradation (Chang et al., 2011; Tresse et al., 2010), but
do impair autophagosome maturation (Ju et al., 2009; Tresse
et al., 2010), despite the fact that VCP is essential for both of
these processes. Pathogenic VCP mutations have also been
shown to impair aspects endolysosomal sorting and aspects
of myosin assembly (Janiesch et al., 2007; Ritz et al., 2011).
The results presented here demonstrate that VCP is essential
to mitochondrial quality control by the PINK1/parkin pathway
in vitro and in vivo and show that this function must be included
in the list of those functions impaired by pathogenic VCP
mutations.
EXPERIMENTAL PROCEDURES
Cell Culture
Mouse embryonic fibroblasts (MEFs), HeLa cells, and C2C12 cells were
cultured in DMEM (Hyclone) supplemented with 10% FBS (Hyclone) and
GlutaMax-1X (GIBCO). For SH-SY5Y cells, DMEM:F-12 (GIBCO) was used
with the same supplements. Drugs were used at the following final concentra-
tions: CCCP at 20 mM, epoxomicin at 100 nM, bafilomycin at 10 mM, and
MG132 at 5 mM. Mito-Cerulean stable MEFs were generated by retroviral
transfection of a mito-Cerulean plasmid (gift of Fabien Llambi) using Phoenix
Eco cells (Orbigen; RVC-10002). The YFP-Parkin HeLa stable line (Narendra
et al., 2008) was a gift from Richard Youle.
Plasmids and Transfections
HeLa cells, MEFs, and SH-SY5Y cells were transfected using FuGENE6
transfection reagent (Roche; 1988387001) and C2C12 cells were transfected
using Lipofectamine 2000 transfection reagent (Invitrogen; 11668-027)
following the manufacturers’ instructions. The EGFP-VCP wt and mutant
plasmids were previously described (Tresse et al., 2010). VCP-mCherry was
constructed by releasing VCPwt from the EGFP-VCPwt plasmid and inserting
the gene into the BamHI and HindIII sites of pmCherry-N1 (Clontech). Flag-
Parkin was previously described (Lim et al., 2007). EGFP-Parkin wild-type
and T240R were previously described (Lee et al., 2010). mCherry- and
YFP-Parkin plasmids were gifts from Richard Youle. The p47-, npl4-, and
ufd1-GFP were made by recombination of the Gateway entry clone withNeuron 78, 65–80, April 10, 2013 ª2013 Elsevier Inc. 77
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VCP and the PINK1/Parkin PathwaypcDNA-DEST47 (Invitrogen) using LR Clonase II Enzyme (Invitrogen,
11791-020) following the manufacturers’ instructions. The entry vectors
(HsCD00042210, HsCD00041106, and HsCD00081676, respectively) were
purchased from Dana-Farber/Harvard Cancer Center DNA Resource Core.
RNAi knockdown of target genes were performed by transfection of
ON-TARGET plus-SMARTpool siRNA (Dharmacon) using Lipofectamin RNAi
Max (Invitrogen): nontargeting (1081195), VCP (057592 for mouse cells and
008727 for human cells), p47 (198326), npl4 (199469), ufd1 (011672), and
parkin (50873).
Neuronal Cell Culture and Transfection
For the generation of primary neurons, dorsal root ganglia were dissected from
postnatal mice (P1) and then dissociated and cultured on glass coverslips
coated with poly-D-lysine (Sigma) and Laminin (BD Biosciences). The cultures
were maintained at 37C in Leibovitz’s L-15 medium (phenol red free;
Invitrogen) supplemented with 0.6% glucose (Sigma), 2 mM L-glutamine
(Sigma), 5 ng/ml nerve growth factor (2.5S; Sigma), 10% fetal bovine serum
(Thermo Scientific Hyclone), and 0.5% hydroxypropylmethylcellulose
(Methocel; Sigma). Cells were transfected in suspension before plating by
electroporation with 75 to 100mg/ml DNA and 2mMsiRNA by using an Amaxa
Nucleofector (SCN program 6; Lonza,Walkersville, MD). Neurons were treated
with either 10 mM CCCP (Sigma) in DMSO (Fisher Scientific) or with DMSO
alone, supplemented with Z-VAD-FMK (Sigma) for 24 or 48 hr, after which
they were washed two times with PBS. The cells were then fixed and observed
using a spinning-disc confocal Marianas system (Intelligent Imaging Innova-
tions, Denver, CO) configured on a Zeiss Axio Observer. Colocalization was
confirmed by line intensity analysis using Slidebook 5.0 (Intelligent Imaging
Innovations).
Quantitative Real-Time PCR
Total RNA was isolated with Trizol (Invitrogen) from MEFs. qPCR performed
with TaqMan RNA-to Ct 1 step-kit (Applied Biosystems; 4392938). The primers
Mm01243864_g1, Mm01253310_m1, Mm00495912_m1, and 4352339E-
1009033 were used to detect the p47, npl4, ufd1, and GAPD levels, re-
spectively. qPCR was performed in an Applied Biosystems 7900HT Fast
Real-Time PCR System using the following cycling parameters: 48C
(15 min), 95C (10 min), and 40 cycles of 95C (15 s), 60C (1 min). All PCR
experiments were conducted in triplicates.
Microscopy
For immunofluorescence, MEFs were plated on chamber slides (Lab-Tek;
154917). Cells were fixed with 4% paraformaldehyde and then washed twice
with PBS and once with NH4Cl (10 mM). The cells were permeabilized with
0.2% saponin and blocked with 10% horse serum and 0.1% saponin.
Anti-Tom20 antibody (Santa Cruz Biotechnology; FL-145) was used at
a 1:50 dilution. Coverslips were mounted onto microscope slides using
ProLong Gold Antifade Reagent with DAPI (Invitrogen; P3691). Cells were
observed with a LSM510 (Zeiss) confocal microscope with a 633 objective.
Anti-cytochrome C and anti-ubiquitin immunostaining were performed as
described in (Lee et al., 2010).
For live imaging, MEFs or HeLa cells were plated on glass-bottom dishes
(MatTek Corporation; P35GC-1.5-10-C) or chambered coverglass (Lab-Tek;
155382). Cells were observed with a spinning-disc confocal Marianas system
(Intelligent Imaging Innovations, Denver, CO) with a 633 objective. Movies
were collected on a Marianas confocal microscope with 403 objective, with
3 min intervals during the first 2 hr and 10 min intervals during the remainder
of the time period.
Western Blotting
VCP (1:3000; Thermoscientific; MA3-004), tubulin (1:3000; Sigma-Aldrich;
T5168), GAPDH (1:500; Sigma-Aldrich; G9545), VDAC 1-2-3 (1:500; Thermo
Scientific; PA1-954A), b-actin (1:1000; Sigma-Aldrich; A5316), and parkin
(abcam; 15954) were visualized by the Odyssey system (Li-Cor). MFN1/2 anti-
body (1:50, Santa Cruz, Z-6) was detected using ECL (34096, Pierce). For
western blotting of Drosophila samples the following antibodies were used
and detected using ECL or theOdyssey system: HA high affinity (1:500; Roche;
11867423001), VCP (311-325) (1:3000; Sigma-Aldrich; SAB1100655), and78 Neuron 78, 65–80, April 10, 2013 ª2013 Elsevier Inc.Actin (1:50,000; Chemicon; MAB1501). Western blots were quantified using
ImageJ software (NIH).
Statistical Analysis
Statistical analysis of mitochondrial clearance and protein quantitation were
evaluated by the paired Student’s t test at p < 0.05 with GraphPad software.
Fly Stocks
The EDTP-GAL4, Hsp70-GAL4, GMR-GAL4, and ey-GAL4 drivers were
obtained from the Bloomington Drosophila stock center. GFP-dVCP protein
trap line (TER94CB04973) was obtained from the Spradling Lab (http://flytrap.
med.yale.edu/). The UAS-dMfn-HA transgenic line was a kind gift from Andrea
Daga. The UAS-PINK1 transgenic line and PINKB9mutant were kind gifts from
J.K. Chung. The park25 mutants were previously characterized (Greene et al.,
2003). UAS-dVCP wt, UAS-dVCP R152H, and UAS-dVCP A229E transgenic
flies were previously described (Ritson et al., 2010). MHC-GAL4 and OK371-
GAL4 were used to drive expression of dVCP in muscles and motor neurons,
respectively.
Adult Muscle Preparation
Adult flies were embedded in a drop of OCT compound (Sakura Finetek; 4583)
on a glass slide, frozen with liquid nitrogen, and bisected sagitally by a razor
blade. After fixation with 4% paraformaldehyde in PBS, hemithoraces were
stained by Texas Red-X-Phalloidin (Invitrogen; T7471) according to the manu-
facturer’s instructions. Samples were mounted in Fluoromount-G mounting
medium (SouthernBiotech; 0100-01) and examined by DMIRE2 (Leica)
with 103 and 1003 objectives for musculature and sarcomere structure,
respectively.
Thoracic Indentation and Pupal Lethality Phenotypes
To quantitate the frequency of thoracic indentations, individual flies were
examined 2 to 5 days after eclosion to determine whether there were indenta-
tions in the cuticle of the thorax, indicative of flight muscle degeneration. n > 90
were examined for PINK1B9 mutants and n > 40 were examined for park25
mutants. To monitor viability, total and empty pupal cases were counted
(n > 200 from three independent crosses).
Drosophila Neuronal Phenotype Analysis
Five wandering 3rd-instar larvae for each group were collected, washed, and
placed onto a 3% agarose gel in a 10 cm dish. After 5 min acclimation, larval
crawling behavior was recorded by a digital camera for 30 s (15 fps). Each
group was tested three times. Moving distances of each larva were manually
measured with ImageJ. Neuromuscular synaptic bouton number (n = 18)
and active zone density (n = 12) were measured as previously described
(Nedelsky et al., 2010; Smith and Taylor, 2011) with slight modification. Active
zone area and presynaptic area stained by NC82 and anti-HRP antibody were
measured with ImageJ and the ratio of active zone area/presynaptic area was
calculated. Ghost boutons were counted with the same samples prepared for
synaptic bouton number counting. NMJs at muscle 4 were used for all anal-
yses. To check integrity of adult neuromuscular junctions, escapers were
dissected and stained with presynaptic anti-HRP antibody (1:200, Jackson
Immunoresearch) and postsynaptic anti-discs large antibody (1:50, DSHB)
and ventral abdominal muscles were examined.
Coimmunoprecipiation from Drosophila Brains
Fifty brains were dissected from 3rd-instar larvae expressing dMFN-HA
in motor neurons with a TER94CB04973 allele (TER94CB04973, OK371/+; UAS >
dMFN-HA/+). The dissected brains were lysed and immunoprecipitated by
anti-GFP agarose beads (Chromotek; ACT-CM-GFA) following the manu-
facturer’s instruction. Agarose beads were used as a binding control.
Electron Microscopy
One-day-old adult thoraces from the appropriate genotypes were fixed in 4%
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) with 5% sucrose
and postfixed in 0.2% osmium tetroxide in 0.1 M sodium cacodylate buffer
with 0.3% potassium ferrocyanide for 2 hr. After rinsing in same buffer, the
tissue was dehydrated through a series of graded ethanol to propylene oxide,
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VCP and the PINK1/Parkin Pathwayinfiltrated, and embedded in epoxy resin and polymerized at 70C overnight.
Semithin sections (0.5 mM) were stained with toluidine blue for light micro-
scope examination. Ultrathin sections (70 nm) were cut and stained with Rey-
nolds lead citrate. Examinations were made with a JEOL 12003 transmission
electron microscope at 60 kV and imaged using an AMT V600 digital camera.
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